镥-177-PSMA-617 治疗转移性去势抵抗性前列腺癌：VISION 试验的局限性。
Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial.
机构信息
Department of Oncology, Geneva University Hospital, Geneva, Switzerland; Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, CA, USA.
College of Medicine, Texas A&M Health Science Center, Bryan, TX, USA.
出版信息
Eur Urol. 2023 Jul;84(1):4-6. doi: 10.1016/j.eururo.2022.08.022. Epub 2022 Sep 9.
Lu-PSMA was approved in the USA for patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer already treated with androgen receptor pathway inhibition and taxane-based chemotherapy on the basis of results from VISION. Three limitations affected the control arm in VISION: choice of the standard of care was limited, some patients initially deemed ineligible for taxane later received it, and there was a high attrition rate. VISION is an example of the many challenges in modern oncology trials. The direct and indirect costs of Lu-PSMA also mean that this therapy is likely to be out of reach for many nations, deepening global inequities in health care access.
Lu-PSMA 基于 VISION 研究结果在美国获批用于治疗经雄激素受体通路抑制和紫杉烷类化疗治疗的前列腺特异性膜抗原阳性转移性去势抵抗性前列腺癌患者。VISION 研究的对照组存在三个局限性：标准治疗选择受限，一些最初被认为不符合接受紫杉烷类药物治疗条件的患者后来接受了该治疗，以及患者流失率较高。VISION 是现代肿瘤学试验中诸多挑战的一个例子。Lu-PSMA 的直接和间接成本也意味着，许多国家可能无法获得这种治疗方法，从而加深了全球医疗保健获取方面的不平等。
Zotero 插件